Alembic Pharmaceuticals Q1FY22 net slides to Rs. 164.52 Cr
News

Alembic Pharmaceuticals Q1FY22 net slides to Rs. 164.52 Cr

The US business faced price erosion due to increased competition.

  • By IPP Bureau | July 27, 2021

Alembic Pharmaceuticals has reported total income of Rs.1327.91 crores during the period ended June 30, 2021 as compared to Rs.1284.34 crores during the period ended March 31, 2021.

The company reported total income Rs.1341.64 crores during the period ended June 30, 2020.

The company has posted net profit of Rs.164.52 crores for the period ended June 30, 2021 as against net profit of Rs.250.70 crores for the period ended March 31, 2021. It posted net profit of Rs.301.46 crores for the period ended June 30, 2020.

Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said "The India business grew exceptionally well and outpaced the Industry, we hope to see this momentum continuing due to the initiatives undertaken recently. The US business faced price erosion due to increased competition. However, our long term view of the US market remains intact."

Upcoming E-conference

Other Related stories

Startup

Digitization